(Q38091371)

28 August 2017

title

Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield (English)

1 reference

28 August 2017

0 references

Russell M Medford

1

1 reference

28 August 2017

T Forcht Dagi

series ordinal

2

1 reference

28 August 2017

Robert S Rosenson

series ordinal

3

1 reference

28 August 2017

Margaret K Offermann

series ordinal

4

1 reference

28 August 2017

publication date

1 May 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

321

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-013-0321-0

28 August 2017

exact match

0 references

cites work

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The cost of drug development: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Drug development costs when financial risk is measured using the Fama-French three-factor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Personalized medicine: the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Breast cancer assessment tools and optimizing adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Molecular-targeted therapies in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The BATTLE to personalize lung cancer prevention through reverse migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Gene-expression-based prognostic assays for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Ischemic heart disease, atherosclerosis, and longevity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

European guidelines on cardiovascular disease prevention in clinical practice: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Measurement issues related to lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Biological activities of HDL subpopulations and their relevance to cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Biomarkers and surrogate markers: an FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Adaptive licensing: taking the next step in the evolution of drug approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0321-0

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

21 January 2018

1 reference

12 December 2020

Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges

1 reference

12 December 2020

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

1 reference

12 December 2020

Risk factors. Oncotype DX assay predicts local recurrence in breast cancer

1 reference

12 December 2020

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study

1 reference

12 December 2020

NIH budget. Boom and bust

1 reference

12 December 2020

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development

1 reference

12 December 2020

Mouse models of atherosclerosis

1 reference

12 December 2020

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

12 December 2020

10.1007/S11883-013-0321-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1020025002

0 references

1 reference